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A B S T R A C T
Purpose: To assess efﬁcacy/tolerability of ezogabine (EZG)/retigabine (RTG) in combination with
speciﬁed monotherapy antiepileptic drug (AED) treatments in adults with uncontrolled partial-onset
seizures using a ﬂexible dosing regimen.
Methods: NCT01227902 was an open-label, uncontrolled study of ﬂexibly dosed EZG/RTG. Adults with
partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC),
lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA). The study comprised a screening/
baseline phase, a 4-week titration phase (initiation on 150 mg/day [50 mg three times daily (TID)] with
weekly increases of 150 mg/day [50 mg TID] over 4 weeks to 600 mg/day), and a ﬂexible dose evaluation
(FDE) phase (optional weekly dose changes of 50–150 mg/day, to an optimal daily dosage [300–
1200 mg/day]). The primary efﬁcacy endpoint was percentage of patients experiencing a 50% reduction
from baseline in partial seizure frequency (responder rate) during the treatment phase (titration and FDE
phases). Safety and tolerability were also assessed.
Results: Patients (N = 203) were enrolled and received 1 dose of EZG/RTG. The dose of EZG/RTG
prescribed most frequently during the treatment phase was 600 mg/day for all AED groups. Responder
rates during the treatment phase were: 40.0% (CBZ/OXC), 32.0% (LTG), 50.0% (LEV), and 56.9% (VPA).
Treatment-emergent adverse events occurred in 82% (CBZ/OXC), 76% (LTG), 73% (LEV), and 67% (VPA) of
patients; most were of mild-to-moderate intensity.
Conclusions: EZG/RTG was effective as adjunctive therapy to CBZ/OXC, LTG, LEV, and VPA, using a ﬂexible
dosing regimen, in adults with partial-onset seizures; safety and tolerability were consistent with that
previously observed.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Abbreviations: AED, antiepileptic drug; AUA, American Urological Association; CBZ/OXC, carbamazepine/oxcarbazepine; C-SSRS, Columbia Suicide Severity Rating Scale; ECG,
electrocardiogram; EZG/RTG, ezogabine/retigabine; FDE, ﬂexible dose evaluation; ITT, intent-to-treat; LTG, lamotrigine; LEV, levetiracetam; OLE, open-label extension; PGI-
C, Patient Global Impression of Change; PVR, post-void residual; SF-36v2, Short Form-36 Health Survey version 2; SOC, system organ class; TEAE, treatment-emergent adverse
events; TESAE, treatment-emergent serious adverse event; TID, three times daily; VPA, valproic acid.
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Ezogabine (EZG; United States adopted name)/retigabine (RTG;
international nonproprietary name) is an antiepileptic drug (AED)
that reduces neuronal excitability by enhancing the activity of
KCNQ (KV7) potassium channels [1]. In the EU, EZG/RTG is
indicated for use as adjunctive therapy for drug-resistant partial-
onset seizures in adults for whom other AEDs have proved
inadequate or have not been tolerated [2]. In the US, EZG/RTG
(600–1200 mg daily) is approved for adjunctive treatment of
partial-onset seizures in adults who have responded inadequately
to several AEDs and for whom the beneﬁts outweigh the risk of
ophthalmic adverse events [3].
Despite the availability of several AEDs, up to 30% of patients
remain resistant to treatment [4,5]. Adjunctive therapy is
warranted for such patients, but there are limited clinical data
on AED combinations for treatment optimization [6]. Results from
randomized controlled trials (RCTs), using strict inclusion/exclu-
sion criteria and titration to one of three ﬁxed doses, indicated that
EZG/RTG was superior to placebo as an adjunctive therapy in
patients with partial-onset seizures [7–9]. In approximately 70% of
patients, EZG/RTG was used as an adjunct to 2 AEDs [7–9]. EZG/
RTG was efﬁcacious and generally well tolerated irrespective of the
number of concomitant AED(s) [10]. Analyses by AED combina-
tions were confounded, however, as >75% of patients received 2
concomitant AEDs and sample sizes varied [11].
The current Phase IIIb trial was a hypothesis-generating study
designed to assess the efﬁcacy and tolerability of EZG/RTG
combined with speciﬁed AED monotherapies in adults with
partial-onset seizures using a ﬂexible dosing regimen. This
open-label study evaluated the efﬁcacy, safety and tolerability,
and health outcomes of EZG/RTG treatment in settings likely to
reﬂect clinical practice. The study used a lower starting dose and a
slower titration to a lower target dose of EZG/RTG than in pivotal
trials [7–9]. The dose was then managed in the range 300–
1200 mg/kg according to individual patient response to assess
whether a lower starting dose and individualization of treatment
could improve tolerability of EZG/RTG in clinical practice.1200
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Fig. 1. Study design.
EZG/RTG = ezogabine/retigabine; V = visit.
Titration (start of Week 1 to end of Week 4) – dose increase by 150 mg/day per week.
Flexible dose evaluation (start of Week 5 to end of Week 20) – dose adjustment betw2. Methods
2.1. Study design
This was an open-label, multicenter, multinational, Phase IIIb
exploratory study (NCT01227902). After a screening period (14
days) and a prospective baseline phase (8 weeks), patients
receiving a stable dosage of one of four AEDs (carbamazepine
[CBZ]/oxcarbazepine [OXC], lamotrigine [LTG], levetiracetam
[LEV], or valproic acid [VPA]) from 4 weeks before the start of
collection of baseline seizure data initiated EZG/RTG 150 mg/day
(50 mg three times daily [TID]). With the sponsor’s prior
authorization, a maximum of 4 weeks’ retrospective seizure
data could replace up to the ﬁrst 4 weeks of the baseline phase
provided a daily seizure diary was completed (including number
and type of seizures). The dose was up-titrated to 600 mg/day in
increments of 150 mg/day (50 mg TID) weekly over 4 weeks
(titration phase). Patients then entered a 16-week ﬂexible dose
evaluation (FDE) phase, during which the total daily dose could
be changed weekly by 50–150 mg/day until the optimal dose for
efﬁcacy and tolerability was achieved in the investigator’s
opinion. The allowable range of total daily doses for the FDE
phase was 300–1200 mg/day. After completing the FDE phase,
patients who had beneﬁted from the regimen were invited to
enroll in an open-label extension (OLE). There was a 3-week
taper/follow-up phase for patients who did not enter the OLE or
withdrew prematurely from the study (unless safety concerns
necessitated immediate withdrawal; for study design, see
Fig. 1).
The study protocol, amendments, and consent form were
approved by the appropriate national, regional, or investigation-
al center ethics committee or institutional review board in
accordance with the International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuticals
for Human Use, Good Clinical Practice and all applicable
regulatory requirements, and the principles of the Declaration
of Helsinki. All patients provided written informed consent prior
to participation.9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
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Table 1
Baseline patient demographics and characteristics by concurrent AED group and combined concurrent AED groups.
CBZ/OXC
(n = 56)
LTG
(n = 51)
LEV
(n = 44)
VPA
(n = 52)
Combined
(N = 203)
Male, n (%) 23 (41) 25 (49) 19 (43) 26 (50) 93 (46)
Mean age, y (range) 40.6 (19–76) 38.2 (19–65) 37.0 (18–79) 40.3 (18–72) 39.1 (18–79)
Age group, n (%)
65 years 5 (9) 1 (2) 3 (7) 3 (6) 12 (6)
Race, n (%)
White 55 (98) 45 (88) 39 (89) 49 (94) 188 (93)
Asian 1 (2) 6 (12) 5 (11) 3 (6) 15 (7)
Number of previously failed AEDs, n (%)
0–1 14 (25) 15 (29) 17 (39) 28 (54) 74 (36)
2–5 32 (57) 28 (55) 22 (50) 21 (40) 103 (51)
6 10 (18) 8 (16) 5 (11) 3 (6) 26 (13)
AED = antiepileptic drug; CBZ/OXC = carbamazepine/oxcarbazepine; LEV = levetiracetam; LTG = lamotrigine; VPA = valproic acid.
1 Regular eye and skin monitoring was not performed as the study was
completed by May 2013 when regular monitoring was advised for retinal
abnormalities and changes in visual function in EZG/RTG-treated patients [12].
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Patients were enrolled in accordance with the inclusion and
exclusion criteria (Supporting information Table S1). The number of
previously failed AEDs over each patient’s lifetime (0–1, 2–5, 6)
was summarized. Previously failed AED was deﬁned as an AED
formerly taken which, in the investigator’s opinion, had failed due to
lack of efﬁcacy, tolerability, or both. Current monotherapy to which
EZG/RTG was added was not considered a previously failed AED.
2.3. Efﬁcacy assessments
Patients (or caregivers) were required to maintain a daily
written seizure calendar throughout the study. Patients received a
calendar at every visit starting with screening/baseline and were
trained to complete it; study personnel transcribed the daily
information from the calendar into the electronic case report form.
Calendar review included seizure counts, codes, and checks for
completeness. The number of seizures by type and duration of
episodes of innumerable seizure activity (deﬁned as continuous
seizure activity where individual seizures occurred so frequently
that the caregiver could not distinguish the commencement and
completion of each seizure) were recorded in the seizure calendar
during all phases. The primary efﬁcacy endpoint was the responder
rate (percentage of patients with 50% reduction in partial seizure
frequency from baseline) summarized by concurrent AED during
the treatment phase (titration and FDE phases combined).
Secondary efﬁcacy endpoints included the partial seizure
responder rate during the treatment phase (summarized for all
concurrent AEDs combined), percentage change in partial seizure
frequency from baseline during the treatment phase, and percentage
change in partial seizure frequency summarized by the following
categories: no change or an increase (including >25% increase and
0–25% increase), and any decrease (including >0–<50% decrease,
50–75% decrease, and >75–100% decrease). Both percentage change
in partial seizure frequency and partial seizure frequency by
category were summarized by concurrent AED and by all concurrent
AEDs combined.
Exploratory efﬁcacy endpoints included responder rate during
the treatment phase summarized by the number of previously failed
AEDs (0–1, 2–5, 6) at baseline and, for patients who entered the
FDE phase, responder rate and percentage of patients who were
seizure-free during FDE. Patients who withdrew during FDE were
considered seizure-free if they withdrew before experiencing a
seizure in FDE.
2.3.1. Safety and tolerability assessments
Safety and tolerability endpoints included type and incidence of
treatment-emergent adverse events (TEAEs) recorded during the
treatment and taper/follow-up phases. Time to premature studydiscontinuation was recorded, and vital signs, electrocardiogram
(ECG), body weight, and clinical laboratory variables were moni-
tored throughout. Suicidal ideation and behavior was assessed with
the Columbia Suicide Severity Rating Scale (C-SSRS). Change from
baseline urinary bladder function was assessed with the American
Urological Association (AUA) Symptom Scale; post-void residual
(PVR) bladder volumes were assessed by ultrasound.1
The optimal dose of EZG/RTG for efﬁcacy and tolerability was
assessed by the investigator at Visit 7 (20-week visit). The
incidence of new seizure types during the treatment phase (types
not occurring before the study or during the baseline phase) was
recorded as an exploratory endpoint.
2.3.2. Health outcomes assessments
Health outcomes assessments included evaluation of worry and
activity limitations using the Patient Global Impression of Change
(PGI-C) at Visit 7 (20-week visit) and the change from baseline
scores on the Short Form-36 Health Survey version 2 (SF-36v2)
during the treatment phase.
2.4. Statistical analyses
Analysis focused on descriptive statistics in this open-label
study. The safety population, comprising patients who took at least
one dose of EZG/RTG, was used for summaries of baseline
characteristics and safety. The intent-to-treat (ITT) population
included all patients in the safety population who provided at least
one post-baseline efﬁcacy assessment and was used for summaries
of all efﬁcacy and health outcomes variables.
Target enrollment (i.e., number entering the Titration Phase)
was planned for approximately 53 patients in 3 of the AED
groups. If 85% of patients were evaluable (i.e., in the ITT
population), there would be approximately 45 patients in 3
AED groups; thus, a total ITT population between 135 and
180. Within any of the AED subgroups of 45, a two-sided 95%
conﬁdence interval for the primary efﬁcacy endpoint (response
rate), around the expected response rate of 48%, would have a half-
width of 14.6%. An analogous conﬁdence interval for the minimum
total sample size of 135 would have a half-width of 8.4%.
3. Results
3.1. Study population and patient withdrawal
A total of 227 patients entered the screening phase; 203
enrolled in the study (see Table 1 for baseline demographics/
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AED groups. Patients were enrolled from 12 countries; 92% were
enrolled from 6 countries (Supporting information Table S2).
AED groups differed with respect to the number of previously
failed AEDs at baseline (Table 1). The baseline percentage of
patients with 0–1 previously failed AED was greatest in the VPA
group (54%). The CBZ/OXC and LTG groups had the greatest
baseline percentages of patients with 2–5 previously failed AEDs
(57% and 55%, respectively) and 6 previously failed AEDs (18%
and 16%, respectively).
Sixty (30%) patients withdrew during the treatment phase
(28 [14%] during titration; 32 [16%] during FDE), mainly owing to
TEAEs (Supporting information Fig. S1); 143 patients completed
the study. Three patients in the safety population (one each from
the CBZ/OXC, LTG, and VPA groups) did not provide at least one
post-baseline efﬁcacy evaluation and were excluded from the ITT
population. Kaplan–Meier estimates of time to withdrawal during
the treatment phase are summarized in Fig. 2.
3.2. Treatment exposure
The total daily dose of EZG/RTG most frequently prescribed in
the treatment phase was 600 mg for all AED groups. Study protocol
permitted modiﬁcation of the EZG/RTG maintenance dose
according to clinical response and tolerability. For those who
completed the FDE phase, the median optimal total daily dose as
determined by the investigator was 700 mg/day in the LTG group
and 600 mg/day in each of the other AED groups (Supporting
information Table S3). Of the 134 FDE completers for whom an
optimal dose was identiﬁed, a daily dose of <600 mg was identiﬁed
for 40 (30%) and 900 mg for 26 (19%).1.0
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Fig. 2. Kaplan–Meier graph of time to withdrawal during the treatment phase, by
concurrent AED group, following administration of EZG/RTG.
AED = antiepileptic drug; CBZ/OXC = carbamazepine/oxcarbazepine; EZG/RTG =
ezogabine/retigabine; LEV = levetiracetam; LTG = lamotrigine; VPA = valproic acid.EZG/RTG titration was initiated at 150 mg/day. After titration to
600 mg/day and dose adjustment in the range of 300–1200 mg/
day, responder rate in the treatment phase (titration and FDE)
ranged from 32% in the LTG group (where median optimal dose of
EZG/RTG was highest) to 57% in the VPA group.
3.3. Efﬁcacy
3.3.1. Responder rates
The responder rate for the ITT population during the treatment
phase, and for the FDE phase only (patients in the ITT population
who entered the FDE phase) in each AED group, is shown along
with 95% conﬁdence intervals in Fig. 3A. The responder rate was
highest in the VPA group in both the treatment and FDE phases
(56.9% and 66.0%, respectively); responder rates in the combined
AED group in the treatment and FDE phases were 44.5 and 54.0%,
respectively. Sensitivity analyses to assess the effect of withdrawal
during both titration and FDE phases on the responder rates
yielded similar results for the treatment and FDE phases
(Supporting information Table S4). Percentages of patients in
the ITT population with no change or increase, >0–<50% decrease,
50–75% decrease, and >75–100% decrease in seizure rate fromn = 55 n = 47 n = 50 n = 45 n = 44 n = 35 n = 51 n = 47 n = 200 n = 174
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Fig. 3. Responder rates (%) following administration of EZG/RTG in the ITT
population during the treatment phase, and the FDE phase only for patients in the
ITT population who entered the FDE phase (A), and categories of change from
baseline partial seizure rate during the treatment phase (B), by concurrent AED
group and combined concurrent AED groups.
A. The intervals shown represent 95% CI.
B. Percentages may not add to 100% because of rounding.
AED = antiepileptic drug; CBZ/OXC = carbamazepine/oxcarbazepine; CI = conﬁdence
interval; EZG/RTG = ezogabine/retigabine; FDE = ﬂexible dose evaluation; ITT = intent-
to-treat; LEV = levetiracetam; LTG = lamotrigine; VPA = valproic acid.
Table 2
Summary of responder rates (n/n [%]) in the ITT population following administration of EZG/RTG during the treatment phase, by number of previously failed AEDs and
concurrent AED group and combined concurrent AED groups.
Number of previously failed AEDs (n) CBZ/OXC
(n = 55)
LTG
(n = 50)
LEV
(n = 44)
VPA
(n = 51)
Combined
(n = 200)
0–1 10/14 (71.4) 7/15 (46.7) 9/17 (52.9) 15/28 (53.6) 41/74 (55.4)
2–5 10/31 (32.3) 7/28 (25.0) 10/22 (45.5) 14/20 (70.0) 41/101 (40.6)
6 2/10 (20.0) 2/7 (28.6) 3/5 (60.0) 0/3 (0.0) 7/25 (28.0)
AED = antiepileptic drug; CBZ/OXC = carbamazepine/oxcarbazepine; EZG/RTG = ezogabine/retigabine; ITT = intent-to-treat; LEV = levetiracetam; LTG = lamotrigine; VPA =
valproic acid.
n/n (%), responder rate in corresponding group by number of previously failed AEDs.
Percentages may not equal 100% because of rounding.
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shown in Fig. 3B.
As an exploratory endpoint, the responder rate in the ITT
population in the treatment phase was analyzed by number of
previously failed AEDs using the ranges 0–1, 2–5, and 6 used
previously to assess treatment response according to number of
previously failed AEDs (Table 2) [13]. In the combined AED group,
the highest responder rate was seen in patients with 0–1
previously failed AED; there was a trend toward a decreasing
responder rate as the number of previously failed AEDs increased
(Table 2 and Supporting information Table S5).
3.3.2. Overall seizure frequency and seizure freedom
The median reductions in partial seizure frequency in the
treatment phase were 23.7% (CBZ/OXC), 41.9% (LTG), 48.7% (LEV),
and 59.0% (VPA). The median reduction in partial seizure frequency
in patients in the combined AED group was 44.5% (n = 200). Five of
174 patients in the combined AED group who had seizure
recording during the FDE phase were free from seizure during
the FDE phase (two patients each in the CBZ/OXC and LEV groups,
one in the VPA group). All ﬁve seizure-free patients continued
treatment in the OLE.
3.4. Safety and tolerability
3.4.1. Treatment-emergent adverse events
A total of 152 (75%) patients in the safety population reported at
least one TEAE (Table 3). The most common TEAEs by system organ
class (SOC) in the combined AED group were nervous system
disorders (61%), general disorders and administration-site condi-
tions (19%), and psychiatric disorders (11%). TEAEs in the renal andTable 3
Number (%) of patients in the safety population reporting TEAEs following administration
and combined concurrent AED groups.
Any TEAE 
TEAE reported by 5% patientsa
Dizziness 
Somnolence 
Vertigo 
Fatigue 
Asthenia 
TEAEs related to EZG/RTG 
TEAEs leading to permanent discontinuation of EZG/RTG or withdrawal from study 
TEAEs leading to dose reduction or temporary discontinuation 
Any TESAE 
AED = antiepileptic drug; CBZ/OXC = carbamazepine/oxcarbazepine; EZG/RTG = ezogabi
adverse event; TESAE = treatment-emergent serious adverse event; VPA = valproic acid.
a In the combined AED group.urinary disorders SOC were reported by 7% of patients (data not
shown). Of TEAEs experienced by 5% of patients in any group, the
most frequent in the combined AED group were dizziness and
somnolence (26% and 21% of patients, respectively; Table 3). Most
of these TEAEs were mild or moderate. The TEAE reported most
frequently that was assessed as severe was somnolence (3% of
patients in the combined AED group).
Treatment-emergent serious adverse events (TESAEs) were
reported by four patients each in the LTG and LEV groups (8% and
9%, respectively) and one patient (2%) in the VPA group. TESAEs
reported were: cerebrovascular accident, convulsions, dizziness,
epilepsy, grand mal convulsion, headache, partial seizure, partial
seizures with secondary generalization, second degree atrioven-
tricular block, vestibular disorder, vomiting, femoral neck fracture,
invertebral disc disorder, and hypertensive crisis. A TEAE was the
most common reason for withdrawal in the combined AED group
(35 [17%] patients). Incidence of withdrawal for a TEAE ranged
from four patients (8%) in the VPA group to 11 patients (25%) in the
LEV group (Table 3). Somnolence, dizziness, and vertigo were the
most common TEAEs leading to withdrawal. No deaths occurred
during the study.
3.4.2. Vital signs and laboratory assessments
Fewer than 10 patients (5%) at any post-baseline visit had vital
sign changes from screening of potential clinical concern; no
pattern with concurrent AED was apparent. A total of 2% of
patients at any post-baseline visit had a heart rate, PR interval, or
QRS duration of potential clinical concern. There were no notable
ﬁndings in ECG parameters or mean heart rate. Fifteen patients
(8%) had values of post-baseline QT interval corrected with Bazett’s
formula (QTcB) 450 ms (6 [12%] in the LTG group, 4 [8%] in the of EZG/RTG, in the treatment and taper/follow-up phases, by concurrent AED group
Number (%) of patients
CBZ/OXC
(n = 56)
LTG
(n = 51)
LEV
(n = 44)
VPA
(n = 52)
Combined
(N = 203)
46 (82) 39 (76) 32 (73) 35 (67) 152 (75)
15 (27) 15 (29) 14 (32) 9 (17) 53 (26)
11 (20) 8 (16) 7 (16) 17 (33) 43 (21)
5 (9) 7 (14) 3 (7) 4 (8) 19 (9)
6 (11) 5 (10) 5 (11) 1 (2) 17 (8)
1 (2) 2 (4) 5 (11) 4 (8) 12 (6)
44 (79) 37 (73) 30 (68) 32 (62) 143 (70)
12 (21) 8 (16) 11 (25) 4 (8) 35 (17)
22 (39) 15 (29) 14 (32) 19 (37) 70 (34)
0 4 (8) 4 (9) 1 (2) 9 (4)
ne/retigabine; LEV = levetiracetam; LTG = lamotrigine; TEAE = treatment-emergent
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group). Four patients (2%) had values of post-baseline QT interval
corrected with Fredericia’s formula (QTcF) 450 ms (3 [6%] in the
LTG group and 1 [2%] in the CBZ/OXC group). Values of post-
baseline QTcB or QTcF 480 ms (the limit for those with bundle
branch block) or increases >60 ms from baseline were infrequent
(0 to <1% of patients). One (2%) patient in the LTG group had a post-
baseline QTcB 480 ms; no patients had a post-baseline QTcF
480. One (2%) patient in the LEV group had an increase >60 ms
from baseline for both QTcB and QTcF.
Eleven (6%) patients reported an increase in weight of 7%
(5 [10%] in the LTG group, 2 [5%] in the LEV group, and 2 [4%] in
each of the CBZ/OXC and VPA groups). Four (2%) patients decreased
in weight by 7% (2 [4%] in the LTG group and 1 [2%] in each of the
LEV and VPA groups).
There were no clinically signiﬁcant changes in hematology and
clinical chemistry data from baseline, and values were similar
across AED groups (data not shown).
3.4.3. Suicidality
There were no reports of suicide-related AEs during the study.
Three (1.5%) patients, all in the CBZ/OXC group, had no suicidal
ideation or behavior according to baseline C-SSRS, and were noted
to have suicidal ideation (Category 1 – wish to be dead) at one post-
baseline visit.
3.4.4. Bladder function
Post-baseline AUA symptom scale scores were stable compared
with baseline, with scores in the none-to-mild symptom range
(0–7) for 173 (94%) patients (Supporting information Table S6).
One patient in the VPA group had a post-baseline score categorized
as severe (a change from 19 to 27).
Post-baseline PVR bladder ultrasound urine volumes were
normal (deﬁned for the purposes of this protocol as 100 mL) in
172 (97%) patients (Supporting information Table S6). Among the
six (3%) patients with post-baseline volumes >100 mL, three (7%) in
the LTG group shifted from a normal baseline volume to an abnormal
post-baseline volume >200 mL. One of these patients, who was
receiving 1200 mg of EZG/RTG, reported urinary retention as a TEAE.
3.4.5. New seizure types
One (2%) patient each in the LTG and VPA groups reported a new
seizure type: complex partial seizures and partial seizures evolving
to secondarily generalized seizures, respectively.
3.5. Health outcomes
Health outcomes were assessed using the PGI-C at Visit 7 (20-
week visit) and SF-36v2 during the treatment phase. In the
assessment of epilepsy-related worry, most patients (66%) in the
combined AED group showed ‘‘little-to-much improvement’’ on
the PGI-C, while 9% were ‘‘little-to-much worse’’. Most patients
in the combined AED group showed improvement in current
ability to do the things they both needed and wanted to do (58%
and 59%, respectively), with 7% and 6% of patients, respectively,
‘‘a little-to-much worse’’. The VPA group showed more improve-
ment than other AED groups for all PGI-C assessments (data not
shown).
In the combined AED group, median change from baseline to
the end of the treatment phase in both physical and mental
component scores of the SF-36v2 showed a small increase
(0.67 and 0.65, respectively), suggesting improvement in both.
There was a positive median change from baseline in the physical
component score in all except the LEV group. There was a positive
median change from baseline in the mental component score in all
except the CBZ/OXC group (data not shown).4. Discussion
The clinical effectiveness of newer AEDs as adjunctive therapy
in treatment-resistant epilepsy is difﬁcult to predict owing to a
lack of data on effective AED combinations [10,11]. This study
assessed the efﬁcacy, safety, and tolerability of EZG/RTG as an
adjunct to single, speciﬁed AEDs, with a ﬂexible EZG/RTG dosing
regimen as used in clinical practice.
The overall responder rate of patients in the combined AED
group during the treatment phase was 44.5%. This responder rate
was similar to those reported in Retigabine Efﬁcacy and Safety Trial
for Partial Onset Epilepsy 1 (RESTORE 1) (44.4%, ﬁxed dose of
1200 mg/day) and RESTORE 2 (38.6 and 47%, ﬁxed doses of 600 and
900 mg/day, respectively) [7,8]. However, in RESTORE 2, more than
75% of patients were receiving more than one concurrent AED and
had previously failed at least two AEDs, suggesting a more
treatment-resistant patient population than in the present study.
Few published analyses have quantiﬁed the response to AED
treatment as a function of treatment history, or identiﬁed factors
predicting the response to new AEDs [13]. In this study, the highest
responder rate in the combined AED group was in the 0–1 failed
AED category, with a trend toward a decreasing responder rate as
the number of previously failed AEDs increased, suggesting that
EZG/RTG was more efﬁcacious in less treatment-resistant patients.
The association of previous AED failure with response rate has been
reported [13,14]. However, results for individual AED groups in
this study were less clear. The responder rate was highest in the
VPA group; a numerically higher proportion of patients in this
group previously had only 0–1 failed AED compared with the other
groups (54% vs. 25–39%). In line with the above, this suggests that
the VPA group may have included a greater proportion of less
treatment-resistant patients than the other groups, leading to a
higher response rate. However, the responder rate for the VPA
group in the category of 2–5 previously failed AEDs was
numerically greater than in the 0–1 previously failed AED category
(70.0% vs. 53.6%). It is important to note that concomitant AEDs
were not counted as failed and the investigators chose to add EZG/
RTG rather than increasing the dose of baseline AEDs.
According to ‘‘rational polytherapy,’’ some AED combinations
may be more synergistic than others [15]. However, the number of
cases in this exploratory study was small, and numerical values
should be cautiously interpreted.
The frequency of side effects with some AEDs may be reduced
with slower titration [16]. Adjunctive EZG/RTG therapy initiated at
300 mg/day followed by titration of 150 mg/day every 7 days has
been better tolerated than fast or medium titration rates (150 mg/
day every 2 and 4 days, respectively) [17]. However, in this study
using slow titration and ﬂexible dosing, 75% of patients reported
TEAEs (67–82% of patients across AED groups), and a TEAE was the
primary reason for discontinuation (17% of patients overall). TEAE
rates were similar to those in a study using a higher starting dose
and a slow titration rate to reach ﬁxed doses of 600 mg/day or
900 mg/day (73% and 79%, respectively) [7].
TEAEs in the renal and urinary disorders SOC were reported by
7% of patients. EZG/RTG may have a pharmacological effect on the
KCNQ (KV7) channels in bladder muscle, leading to inhibition of
bladder contractility and urinary retention [18]. EZG/RTG has been
reported to cause urinary disorders in 5% of patients [19], and
monitoring of urological symptoms during EZG/RTG use is
recommended [3]. In this study, co-administration of EZG/RTG
with LTG was associated with abnormal urinary function; 3 (7%)
LTG patients had a baseline PVR value 100 mL shifting to a
maximum post-baseline PVR 200 mL, and one of these patients
reported a TEAE of urinary retention.
EZG/RTG has been associated with QT prolongation [3]. How-
ever, use of EZG/RTG as an adjunct to other AEDs was not
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Nevertheless, a proportion of patients showed prolonged QT
intervals post-baseline, especially during co-medication with LTG.
Further studies are needed to verify these ﬁndings, and ECG control
under EZG/RTG should be considered.
Patients treated with EZG/RTG, as with other AEDs, should be
monitored for suicidal behavior and ideation [3]. In this study,
there were no reports of suicide-related TEAEs and no evidence of a
signiﬁcant change from baseline in suicidality with EZG/RTG. It
should be noted that the study sample was relatively selective, as
active suicidal ideation in the past 6 months, a history of suicide
attempt in the past 2 years, or >1 lifetime suicide attempt were
exclusion criteria.
After this study was designed, retinal pigmentation and
discoloration of nails, lips, skin, and mucosa were reported in
other ongoing OLE EZG/RTG trials, and regular monitoring for
pigmentation/discoloration and changes in visual function were
instituted in those trials in May, 2013 [12]. However, by that time,
the current study had already closed. No TEAEs of retinal
pigmentation or nail, lip, skin, or mucosal discoloration were
reported.
Patients in each AED group experienced numerical improve-
ments in health outcomes assessed with the PGI-C. Patients in the
VPA group experienced a slightly greater improvement than those
in the other groups, consistent with improvements in efﬁcacy. Only
minor changes were observed with the SF-36v2, which is not
epilepsy speciﬁc.
This was a short-term, open-label study that lacked randomi-
zation and a control arm, all of which must be considered as study
limitations. Furthermore, patients were enrolled from 12 countries
without restrictions on the percentage of patients from each
country. Consequently, more than 90% of patients were enrolled
from 6 of the 12 participating countries, with Russia as the biggest
contributor. This could be considered an additional limitation
owing to differences in the use of particular AEDs and medical
practice between countries.
Treatment decisions in epilepsy should be made on an
individual basis. Results of the current study may aid clinicians
to target an appropriate dose range of EZG/RTG in the treatment of
partial-onset seizures and to counsel patients about possible
advantages and side-effects of the drug.
5. Conclusions
The ﬂexible dosing regimen used in this study was at least as
effective in improving responder rates as the forced titration and
ﬁxed dosing regimen used in more treatment-resistant patients in
previous studies [7–9], although it did not improve the overall
safety and tolerability proﬁle of EZG/RTG. The highest responder
rate was observed in patients administered EZG/RTG in combina-
tion with VPA. Although no formal comparison of response rates
was performed, there was no evidence of differences in efﬁcacy
between the different EZG/RTG–AED combinations. Factors such as
number of previously failed AEDs and the small number of patients
in this study should be considered when interpreting the results.
This study indicated that EZG/RTG can be an effective adjunct to all
drugs used in this study, namely, CBZ/OXC, LTG, LEV, or VPA, in
patients with partial-onset seizures.
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